Cybrexa Therapeutics in the Hartford Courant

Jan 03, 2019

Cybrexa Therapeutics, a biotechnology company in New Haven’s Science Park, hopes to start a trial in early 2020 to test its first drug, a therapy that targets the cells of solid tumors to prevent damage to healthy tissue. Cybrexa has now identified a lead candidate for the drug, CBX-11, marking a major milestone for the company, president and CEO Per Hellsund said Wednesday.

Read the full article HERE.